Stem definition | Drug id | CAS RN |
---|---|---|
2715 | 155-09-9 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 48 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.44 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 21, 1961 | FDA | COVIS PHARMA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypertensive crisis | 145.51 | 42.88 | 38 | 1159 | 13116 | 50590811 |
Potentiating drug interaction | 121.61 | 42.88 | 26 | 1171 | 3790 | 50600137 |
Drug interaction | 73.58 | 42.88 | 50 | 1147 | 199571 | 50404356 |
Serotonin syndrome | 73.53 | 42.88 | 26 | 1171 | 24687 | 50579240 |
Congenital central nervous system anomaly | 61.51 | 42.88 | 10 | 1187 | 323 | 50603604 |
Atrioventricular septal defect | 56.60 | 42.88 | 9 | 1188 | 252 | 50603675 |
Craniosynostosis | 52.75 | 42.88 | 8 | 1189 | 163 | 50603764 |
Drug dose titration not performed | 51.43 | 42.88 | 9 | 1188 | 455 | 50603472 |
Feeding intolerance | 43.88 | 42.88 | 8 | 1189 | 511 | 50603416 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypertensive crisis | 133.48 | 37.62 | 35 | 995 | 18213 | 64479489 |
Serotonin syndrome | 102.93 | 37.62 | 34 | 996 | 39248 | 64458454 |
Potentiating drug interaction | 71.68 | 37.62 | 18 | 1012 | 7834 | 64489868 |
Drug dose titration not performed | 65.15 | 37.62 | 11 | 1019 | 672 | 64497030 |
Drug interaction | 58.11 | 37.62 | 47 | 983 | 362036 | 64135666 |
Contraindicated product administered | 43.87 | 37.62 | 25 | 1005 | 107804 | 64389898 |
Therapeutic drug monitoring analysis incorrectly performed | 39.50 | 37.62 | 6 | 1024 | 186 | 64497516 |
None
Source | Code | Description |
---|---|---|
ATC | N06AF04 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Monoamine oxidase inhibitors, non-selective |
FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:35469 | antidepressants |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:38623 | monoamine oxidase inhibitors |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
CHEBI has role | CHEBI:131509 | LSD1 inhibitor |
FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Major depressive disorder | indication | 370143000 | |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Feeling agitated | contraindication | 24199005 | |
Orthostatic hypotension | contraindication | 28651003 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Chronic heart failure | contraindication | 48447003 | |
Anxiety | contraindication | 48694002 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Schizophrenia | contraindication | 58214004 | DOID:5419 |
Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Syncope | contraindication | 271594007 | |
Pheochromocytoma | contraindication | 302835009 | |
Myelogram | contraindication | 367401004 | |
Disorder of coronary artery | contraindication | 414024009 | |
Severe Headache Disorder | contraindication | ||
Hypertensive Emergencies | contraindication | ||
Frequent Headache Disorder | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.31 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | IC50 | 7.48 | CHEMBL | CHEMBL | |||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.23 | PDSP | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.29 | PDSP | |||||
Cytochrome P450 2A6 | Enzyme | Ki | 7.19 | WOMBAT-PK | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 6.62 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 5.30 | CHEMBL | |||||
Cytochrome P450 2B6 | Enzyme | IC50 | 5.16 | CHEMBL | |||||
Lysine-specific histone demethylase 1A | Enzyme | Ki | 4.60 | CHEMBL | |||||
Lysine-specific histone demethylase 1B | Enzyme | IC50 | 4.46 | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.23 | PDSP | |||||
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 5.11 | CHEMBL | |||||
Cationic trypsin | Enzyme | Ki | 4.88 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 4.23 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.11 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 6.54 | CHEMBL | |||||
D(3) dopamine receptor | GPCR | Ki | 4.89 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane other | Ki | 5.75 | CHEMBL | |||||
Sigma intracellular receptor 2 | Unclassified | Ki | 5.21 | CHEMBL |
ID | Source |
---|---|
4019953 | VUID |
N0000148038 | NUI |
D00826 | KEGG_DRUG |
13492-01-8 | SECONDARY_CAS_RN |
4018013 | VANDF |
4019953 | VANDF |
C0040778 | UMLSCUI |
CHEBI:9652 | CHEBI |
1LP | PDB_CHEM_ID |
CHEMBL3989843 | ChEMBL_ID |
CHEMBL1179 | ChEMBL_ID |
CHEMBL313833 | ChEMBL_ID |
19493 | PUBCHEM_CID |
DB00752 | DRUGBANK_ID |
CHEMBL3989698 | ChEMBL_ID |
D014191 | MESH_DESCRIPTOR_UI |
986 | INN_ID |
5281 | IUPHAR_LIGAND_ID |
1986-47-6 | SECONDARY_CAS_RN |
3E3V44J4Z9 | UNII |
10734 | RXNORM |
4529 | MMSL |
5608 | MMSL |
84239 | MMSL |
d00884 | MMSL |
001496 | NDDF |
004597 | NDDF |
372891006 | SNOMEDCT_US |
89092006 | SNOMEDCT_US |
89772006 | SNOMEDCT_US |
CHEMBL1255743 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tranylcypromine Sulfate | Human Prescription Drug Label | 1 | 0591-5590 | TABLET, FILM COATED | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 28 sections |
Tranylcypromine Sulfate | Human Prescription Drug Label | 1 | 0591-5590 | TABLET, FILM COATED | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 28 sections |
Tranylcypromine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-739 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-032 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-032 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
PARNATE | Human Prescription Drug Label | 1 | 59212-447 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 28 sections |
PARNATE | Human Prescription Drug Label | 1 | 59212-447 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 28 sections |
TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-210 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2247 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-176 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Tranylcypromine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-183 | TABLET | 10 mg | ORAL | NDA | 16 sections |
Tranylcypromine | Human Prescription Drug Label | 1 | 70954-538 | TABLET | 10 mg | ORAL | ANDA | 29 sections |